Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Pfizer
Timothy Eisen
Consultant or Advisory Role - Astellas Pharma (U); AVEO (U)
Stock Ownership - AstraZeneca
Research Funding - Bayer; GlaxoSmithKline; Pfizer
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Cezary Szczylik
Consultant or Advisory Role - AVEO
Mizue Krygowski
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew P. Krivoshik
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Abbott Laboratories
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Dmitry Nosov
No relevant relationships to disclose